Overview

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is a phaseâ…¡, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
Bevacizumab